Glucagon prescribing and prevention of hospitalization for hypoglycemia in a large health system.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 20 06 2023
revised: 10 07 2023
accepted: 12 07 2023
pmc-release: 01 08 2024
medline: 7 8 2023
pubmed: 16 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

To examine glucagon prescribing trends among patients at high risk of severe hypoglycemia and assess if a glucagon prescription is associated with lower rates of severe hypoglycemia requiring hospital care. Retrospective analysis of electronic health records from a large integrated healthcare system between May 2019 and August 2021. We included adults (≥18 years) with type 1 diabetes or with type 2 diabetes treated with short-acting insulin and/or recent history of hypoglycemia-related emergency department visit or hospitalization. We calculated rates of glucagon prescribing overall and by patient characteristics. We then matched 1:1 those who were and were not prescribed glucagon and assessed subsequent hypoglycemia-related hospitalization. Of 9,200 high risk adults, 2063 (22.4%) were prescribed glucagon. Among patients more likely to be prescribed glucagon were those younger, female, White, living in urban areas, with prior severe hypoglycemia, and with a recent endocrinology specialist visit. In the matched cohort (N = 1707 per arm), 62 prescribed glucagon and 33 not prescribed glucagon were hospitalized for hypoglycemia (adjusted incidence rate ratio 1.71, 95% CI 1.10-2.66; P = 0.018). Glucagon prescribing was infrequent with significant racial and rural disparities. Patients with glucagon prescriptions did not have lower rates of hospitalization for hypoglycemia.

Identifiants

pubmed: 37453512
pii: S0168-8227(23)00595-8
doi: 10.1016/j.diabres.2023.110832
pmc: PMC10527928
mid: NIHMS1918580
pii:
doi:

Substances chimiques

Glucagon 9007-92-5
Hypoglycemic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110832

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK114497
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

JAMA. 2023 Apr 25;329(16):1376-1385
pubmed: 37097356
Endocr Pract. 2018 Oct 2;24(10):861-866
pubmed: 30035620
Endocr Pract. 2013 Sep-Oct;19(5):792-9
pubmed: 23757608
Diabetes Care. 2023 Mar 1;46(3):620-627
pubmed: 36630526
J Gen Intern Med. 2023 May;38(6):1402-1409
pubmed: 36376626
Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110
pubmed: 36507646
JAMA Netw Open. 2020 Jan 3;3(1):e1919099
pubmed: 31922562
Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):479-86
pubmed: 15386817
J Med Econ. 2015 Jun;18(6):420-32
pubmed: 25629654
Endocrine. 2019 May;64(2):233-238
pubmed: 30367442
Diabetes Care. 2015 Feb;38(2):316-22
pubmed: 25492401
BMC Endocr Disord. 2008 Apr 01;8:4
pubmed: 18380903
JAMA Netw Open. 2022 Jan 4;5(1):e2143597
pubmed: 35040969
Curr Diab Rep. 2018 Jun 21;18(8):53
pubmed: 29931579
Diabetes Care. 2022 Oct 1;45(10):2299-2308
pubmed: 35926104
JAMA Intern Med. 2014 Jul;174(7):1116-24
pubmed: 24838229
JAMA Netw Open. 2019 Oct 2;2(10):e1913249
pubmed: 31603490
Mayo Clin Proc. 2010 Dec;85(12 Suppl):S3-4
pubmed: 21106869
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Diabetes Care. 2016 Mar;39(3):363-70
pubmed: 26681726
Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):345-51
pubmed: 26897390
Diabet Med. 2008 Apr;25(4):501-4
pubmed: 18387080
BMJ Open Qual. 2022 Sep;11(3):
pubmed: 36150740
J Diabetes Complications. 2021 May;35(5):107882
pubmed: 33593689
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
J Gen Intern Med. 2017 Oct;32(10):1097-1105
pubmed: 28685482
J Diabetes Complications. 2012 Sep-Oct;26(5):399-406
pubmed: 22699113

Auteurs

Joseph R Herges (JR)

Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Herges.Joseph@mayo.edu.

Jordan D Haag (JD)

Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Haag.Jordan@mayo.edu.

Kimberly A Kosloski Tarpenning (KA)

Department of Pharmacy, Mayo Clinic Health System, Southeast Minnesota region, Owatonna, MN, United States. Electronic address: Tarpenning.Kimberly@mayo.edu.

Kristin C Mara (KC)

Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States. Electronic address: Mara.Kristin@mayo.edu.

Rozalina G McCoy (RG)

Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, United States. Electronic address: McCoy.Rozalina@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH